Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for Vivos Therapeutics (VVOS) over the last 6 years, with Q3 2025 value amounting to 63.9%.

  • Vivos Therapeutics' EBITDA Margin rose 20400.0% to 63.9% in Q3 2025 from the same period last year, while for Sep 2025 it was 87.91%, marking a year-over-year decrease of 56200.0%. This contributed to the annual value of 70.33% for FY2024, which is 506500.0% up from last year.
  • Vivos Therapeutics' EBITDA Margin amounted to 63.9% in Q3 2025, which was up 20400.0% from 119.5% recorded in Q2 2025.
  • In the past 5 years, Vivos Therapeutics' EBITDA Margin ranged from a high of 45.29% in Q2 2024 and a low of 176.7% during Q1 2022
  • Over the past 5 years, Vivos Therapeutics' median EBITDA Margin value was 119.5% (recorded in 2025), while the average stood at 113.46%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first tumbled by -808200bps in 2022, then surged by 848100bps in 2024.
  • Quarter analysis of 5 years shows Vivos Therapeutics' EBITDA Margin stood at 166.39% in 2021, then increased by 12bps to 145.9% in 2022, then increased by 17bps to 121.09% in 2023, then skyrocketed by 42bps to 70.47% in 2024, then grew by 9bps to 63.9% in 2025.
  • Its last three reported values are 63.9% in Q3 2025, 119.5% for Q2 2025, and 123.28% during Q1 2025.